Itoh K, Platsoucas C D, Balch C M
Department of General Surgery, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
J Exp Med. 1988 Oct 1;168(4):1419-41. doi: 10.1084/jem.168.4.1419.
TIL from metastatic melanoma proliferated by greater than 1,000-fold (840-3,675, mean 1,543) after 6 wk in culture of mixtures of TIL and tumor cells with rIL-2 alone. Cytolysis was restricted to autologous tumor cells. CD8+ T cells were the predominant population of TIL before and after expansion, and were primarily responsible for autologous tumor-specific CTL activity. No other rIL-2-activated lymphocytes from peripheral blood, lymph nodes with melanoma metastasis, or TIL from sarcoma or renal cell carcinoma had autologous tumor-specific CTL activity. There were few or no CD16+ NK cells in TIL from metastatic melanoma before or after incubation with rIL-2, respectively. However, TIL from sarcoma or renal cell carcinoma contained a substantial proportion of CD3-CD16+ NK cells, which increased in number in culture with rIL-2. Purified CD16+ NK cells as well as CD3+CD16- T cells from rIL-2-activated TIL of renal cell carcinoma displayed MHC-nonrestricted cytotoxicity. At the clonal level as determined by limiting dilution, 8 of 10 clones from melanoma TIL displayed cytotoxicity restricted to autologous tumor cells, while all 13 clones from renal cancer TIL equally lysed autologous and allogeneic tumor cells. Anti-T cell receptor (TCR)-alpha/beta(WT31) mAb as well as anti-CD3 mAb inhibited autologous melanoma cell-specific CTL activity mediated by rIL-2-activated TIL at the effector phase. These two mAbs also inhibited rIL-2-dependent proliferation of these TIL when added to the culture. Pretreatment of fresh melanoma cells with mAb to MHC antigens followed by washing inhibited specific CTL activity. These results suggest that both TCR-alpha/beta on effector TIL and MHC antigens on fresh tumor cells are involved in the specific immune-recognition. After reaching maximum propagation, TIL from metastatic melanoma responded poorly to rIL-2 alone. However, stimulation with fresh autologous melanoma cells restored both CTL activity and proliferation in response to rIL-2. The latter is associated with IL-2 receptor (Tac antigen) expression on the surface. These results indicate that TIL from metastatic melanomas may have unique characteristics different from lymphocytes obtained from the other sources, and may contain precursor CTL sensitized in vivo to autologous tumor cells, and thus can be propagated in larger numbers with rIL-2 alone while retaining autologous tumor-specific CTL activity.
来自转移性黑色素瘤的肿瘤浸润淋巴细胞(TIL)在与单独的重组白细胞介素-2(rIL-2)一起培养于TIL和肿瘤细胞混合物中6周后,增殖超过1000倍(840 - 3675,平均1543)。细胞溶解作用仅限于自体肿瘤细胞。CD8⁺ T细胞是扩增前后TIL的主要群体,并且主要负责自体肿瘤特异性细胞毒性T淋巴细胞(CTL)活性。来自外周血、伴有黑色素瘤转移的淋巴结的其他rIL-2激活的淋巴细胞,或来自肉瘤或肾细胞癌的TIL均无自体肿瘤特异性CTL活性。在分别与rIL-2孵育之前或之后,来自转移性黑色素瘤的TIL中几乎没有或不存在CD16⁺ 自然杀伤(NK)细胞。然而,来自肉瘤或肾细胞癌的TIL含有相当比例的CD3⁻CD16⁺ NK细胞,其在与rIL-2一起培养时数量增加。来自肾细胞癌的rIL-2激活的TIL中的纯化CD16⁺ NK细胞以及CD3⁺CD16⁻ T细胞表现出MHC非限制性细胞毒性。通过有限稀释法在克隆水平测定,来自黑色素瘤TIL的10个克隆中有8个表现出仅限于自体肿瘤细胞的细胞毒性,而来自肾癌TIL的所有13个克隆均能同等程度地溶解自体和同种异体肿瘤细胞。抗T细胞受体(TCR)α/β(WT31)单克隆抗体以及抗CD3单克隆抗体在效应阶段抑制了由rIL-2激活的TIL介导的自体黑色素瘤细胞特异性CTL活性。当添加到培养物中时,这两种单克隆抗体也抑制了这些TIL的rIL-2依赖性增殖。用针对MHC抗原的单克隆抗体预处理新鲜黑色素瘤细胞然后洗涤可抑制特异性CTL活性。这些结果表明,效应TIL上的TCRα/β和新鲜肿瘤细胞上的MHC抗原均参与特异性免疫识别。在达到最大增殖后,来自转移性黑色素瘤的TIL对单独的rIL-2反应不佳。然而,用新鲜自体黑色素瘤细胞刺激可恢复CTL活性以及对rIL-2的增殖反应。后者与表面的白细胞介素-2受体(Tac抗原)表达相关。这些结果表明,来自转移性黑色素瘤的TIL可能具有与从其他来源获得的淋巴细胞不同的独特特征,并且可能含有在体内对自体肿瘤细胞致敏的CTL前体,因此可以仅用rIL-2大量增殖,同时保留自体肿瘤特异性CTL活性。